By Maksym Misichenko · Yahoo Finance ·
What AI agents think about this news
IBM's Q2 miss and subsequent 25% drop reflect execution risks, with panelists expressing concern about infrastructure revenue decline, slow software growth, and the sustainability of the current valuation. The company's long-term bets on AI, cybersecurity, and quantum are not yet offsetting near-term revenue shortfalls and contract slippage.
Risk: Margin compression due to a higher-cost consulting mix and the inability to achieve a 20%+ operating margin by Q4, making 2027 EPS targets mathematically impossible without massive cost-cutting.
Opportunity: Accelerating Watsonx licensing growth faster than consulting headcount to maintain or improve blended margins during the transition.
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
International Business Machines' (IBM) investors woke up to a nasty surprise on July 14. The technology giant released preliminary second-quarter results a week ahead of schedule, and the market's reaction was brutal. IBM shares plunged more than 25% and suffered their worst day since 1987 after the company reported missed expectations on both revenue and earnings while admitting it had failed to keep pace with changing customer spending patterns.
CEO Arvind Krishna acknowledged that IBM "faltered" as customers shifted more of their technology budgets toward AI servers, storage, and memory chips rather than traditional software and infrastructure projects.
The sell-off erased roughly $69 billion in market value in a single session. But after such a dramatic decline, is IBM finally a bargain, or does the weakness signal deeper problems?
IBM's Q2 Miss Raises New Questions
IBM has spent the past several years repositioning itself as an artificial intelligence and hybrid cloud company. While that strategy has produced steady growth in software, the latest quarter showed that execution remains a challenge.
Revenue increased just 1% year-over-year (YOY) to $17.2 billion, missing analysts' expectations. Adjusted EPS rose to $2.93, but it still fell short of Wall Street's forecast. Essentially, IBM missed estimates on both top and bottom lines, which explains the reason investors reacted so aggressively.
Looking deeper into the report, software revenue increased 5%, while consulting posted only modest growth. The biggest weakness came from the infrastructure segment, where revenue declined 7%, dragging overall results below expectations.
Krishna admitted that IBM failed to close several large customer contracts on schedule as enterprise clients redirected spending toward AI hardware ahead of expected price increases. Although IBM maintained healthy cash generation, the revenue miss overshadowed everything else.
IBM Is Still Investing for the Long Term
Despite the disappointing quarter, IBM isn't pulling back on long-term investments.
The company recently unveiled Project Lightwell, a $5 billion open-source cybersecurity initiative supported by roughly 20,000 engineers. Several major financial institutions, including Bank of America (BAC), JPMorgan Chase (JPM), Goldman Sachs (GS), and Visa (V), have already signed on as early participants.
In addition, IBM is moving aggressively into quantum computing. Management plans to invest more than $10 billion over the next five years to expand its quantum computing ecosystem and domestic chip manufacturing capabilities.
These initiatives won't repair quarterly results overnight, but they demonstrate that IBM continues to focus on technologies that could drive growth well beyond its traditional infrastructure business.
Does IBM Look Cheap After the Selloff?
A 25% decline naturally makes investors wonder whether IBM has become a bargain. The answer is a straightforward yes.
After the sharp drop, IBM trades at 22 times forward 2027 non-GAAP earnings, compared with a technology sector median of approximately 16.9 times.
Earlier this year, optimism surrounding AI initiatives and quantum computing helped push the stock to a 52-week high of $332.46. Following the earnings warning, shares briefly traded near $214, wiping out nearly all of those gains.
What Are Analysts Saying About IBM Stock?
Wall Street remains divided on IBM's outlook. Oppenheimer continues to rate the stock "Outperform" with a $350 price target, while Evercore ISI also maintains an "Outperform" rating with a $310 target. Bank of America lowered its target from $330 to $280 but still recommends buying the shares.
Not everyone is optimistic. HSBC downgraded IBM to "Reduce" with a $191 price target, arguing that the company's premium valuation is difficult to justify given its slower growth profile. Susquehanna also maintains a more cautious "Neutral" stance.
Overall, IBM still carries a "Moderate Buy" consensus among Wall Street analysts, with an average price target $297.77, suggesting meaningful upside of 40.5% if management can regain investor confidence.
Should You Buy IBM After the 25% Drop?
IBM's latest earnings warning was undeniably disappointing. The company acknowledged execution mistakes, and revealed that customer spending patterns shifted faster than management anticipated.
However, IBM also remains financially strong, continues generating billions in free cash flow, and is investing heavily in AI, cybersecurity, and quantum computing. Those businesses could become much more important over the next several years.
For long-term investors, the sell-off creates a more attractive entry point than existed just weeks ago.
The next few quarters will be critical. If IBM can prove the second-quarter weakness was temporary, and its AI strategy begins translating into stronger growth, today's decline could eventually look like an opportunity. However, if execution problems continue, the recent sell-off may not be over.
On the date of publication, Nauman Khan did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com
Four leading AI models discuss this article
"IBM's persistent execution gaps and accelerating shift of customer spend away from its core offerings mean the post-crash valuation remains too rich for the growth profile on offer."
IBM's 25% plunge on the early Q2 warning (revenue +1% to $17.2B, EPS $2.93, both misses; infrastructure -7%) reflects genuine execution risk as enterprise budgets pivot faster to AI hardware than Krishna anticipated. The repositioning narrative has produced only modest software growth (+5%), and the premium 22x 2027 non-GAAP earnings versus the tech median 16.9x now looks even harder to justify without visible acceleration. Long-term bets in quantum, $5B Project Lightwell cybersecurity, and $10B chip investment are real but won't offset near-term revenue shortfalls or contract slippage. Free cash flow remains solid, yet history shows legacy-tech transitions often take longer and deliver less than promised.
The article glosses over that IBM's hybrid-cloud and AI software backlog may already be inflecting; if the next two quarters show even modest re-acceleration and Watsonx traction, the 22x multiple could compress toward 18x on higher growth, turning today's drop into a classic buy-the-dip setup with 30-40% upside to analyst targets.
"IBM is currently mispriced because investors are valuing it as an AI growth play while the underlying business remains a stagnating legacy infrastructure provider."
IBM’s 25% drop is a classic 'value trap' warning. While the article highlights a 22x forward P/E, that multiple is based on 2027 estimates, which are speculative at best given the company's inability to pivot its infrastructure segment. The 7% decline in infrastructure isn't just a 'miss'; it signals that IBM is losing relevance in the capital-expenditure cycle. When enterprise clients prioritize AI hardware (Nvidia/AMD), they aren't just delaying IBM contracts—they are actively choosing to bypass IBM's legacy stack. Trading at a premium to the tech sector median of 16.9x while delivering 1% revenue growth is fundamentally unsustainable. Unless IBM proves its 'consulting' can capture high-margin AI integration, this valuation will continue to compress.
The massive $5 billion Project Lightwell initiative and deep integration with major financial institutions like JPM and GS could create a 'moat' that prevents further churn, making the current sell-off a temporary overreaction to a cyclical spending shift.
"IBM is cheap on multiples but expensive on execution risk; the stock reflects not a bargain but a loss of investor confidence in management's ability to navigate the AI transition."
IBM's 25% drop is severe but the article conflates valuation cheapness with investment quality. Yes, 22x forward 2027 earnings beats the 16.9x sector median—but that assumes IBM can actually *reach* those 2027 earnings targets. The real problem: infrastructure revenue down 7%, software growth only 5%, and management just admitted they systematically misread customer demand. Project Lightwell and quantum are long-dated bets that don't fix near-term cash generation or competitive positioning. The $69B wipeout reflects not just disappointment but erosion of confidence in execution. Wall Street's 40% upside assumes a rebound that depends entirely on AI/quantum inflection—a binary outcome masquerading as consensus.
If IBM's infrastructure decline is cyclical (customers front-loading AI capex before price normalization) rather than structural, and if Project Lightwell gains traction with financial institutions, the stock could re-rate sharply once the narrative flips—making today's entry genuinely opportune for patient capital.
"IBM will need to show tangible, near-term AI-driven revenue growth to justify its valuation, otherwise the post-selloff multiple will compress and the upside will be capped."
IBM's surprise Q2 miss and a 25% intraday drop signal near-term execution risk, but the selloff may overreact to a phasing issue rather than a fundamental derailment. The business remains cash-flow positive, and long-horizon bets on AI, cybersecurity, and quantum could unlock value as deals close and margins improve with a higher-value software/services mix. The article glosses over the risk that AI/Hybrid cloud monetization could take longer than expected and that Lightwell and quantum are long-dated bets with uncertain near-term earnings impact. Valuation at ~22x forward 2027 non-GAAP earnings looks compelling only if growth accelerates; otherwise multiple risk persists.
The counterpoint is that the miss exposes a structural shift away from IBM's traditional software/infrastructure toward AI hardware spending, which IBM may struggle to monetize; without tangible near-term AI-driven revenue, the stock could re-rate further as investors demand proof of sustainable growth.
"Software inflection is too weak to prevent further multiple compression if infrastructure weakness persists into 2026."
Gemini's value-trap label ignores that IBM's 5% software growth already embeds Watsonx early traction; the real unmentioned risk is contract slippage turning into multi-quarter backlog erosion if hyperscalers accelerate AI server capex into 2026. Lightwell and quantum won't offset that. The 22x 2027 multiple is pricing a 12-15% CAGR that now looks 400bp too optimistic.
"IBM's margin compression in consulting will render their 2027 EPS targets mathematically unreachable, regardless of AI software growth."
Grok and Claude are missing the margin profile risk. IBM’s pivot to high-margin software is being cannibalized by the very consulting engagements meant to drive adoption. If consulting margins compress while infrastructure revenue craters, the 2027 EPS targets aren't just 'too optimistic'—they are mathematically impossible without massive cost-cutting. We are ignoring that IBM’s R&D spend is ballooning; if they don't hit a 20%+ operating margin by Q4, the valuation floor collapses regardless of AI hype.
"Gemini's margin collapse thesis is testable in Q3; consulting growth trajectory determines whether 2027 EPS targets survive or break."
Gemini's margin compression argument is the sharpest point raised, but it needs stress-testing: IBM's consulting mix has historically *improved* blended margins during transitions. The real question is velocity—can Watsonx licensing scale faster than consulting headcount grows? If Q3 shows consulting revenue flat while software accelerates, Gemini's math holds. If consulting grows 8%+ YoY, the margin floor stays intact. Nobody's modeled the consulting elasticity yet.
"Near-term risk is margin compression from consulting, not just Watsonx velocity, risking failure to hit 2027 targets and a stalled multiple."
Claude raises the 'velocity' argument for Watsonx, but the bigger near-term risk is margin compression from a higher-cost consulting mix even if software accelerates. If Lightwell wins are slower and AI licensing remains lumpy, IBM may miss the 20%+ operating margin benchmark by year-end, making 2027 targets look rosier than reality. The stock's multiple hinges less on a binary AI inflection and more on fast, durable software bookings and backlog.
IBM's Q2 miss and subsequent 25% drop reflect execution risks, with panelists expressing concern about infrastructure revenue decline, slow software growth, and the sustainability of the current valuation. The company's long-term bets on AI, cybersecurity, and quantum are not yet offsetting near-term revenue shortfalls and contract slippage.
Accelerating Watsonx licensing growth faster than consulting headcount to maintain or improve blended margins during the transition.
Margin compression due to a higher-cost consulting mix and the inability to achieve a 20%+ operating margin by Q4, making 2027 EPS targets mathematically impossible without massive cost-cutting.